China Sxt Pharmaceuticals Inc (SXTC)

$2.16 +1.17 (118.42%)
Market Cap 1.56M
Revenue (ttm) 1.93M
Net Income (ttm) -3.10M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.62%
Debt to Equity Ratio 0.15
Volume 51,734,902
Avg Vol 1,191,632
Day's Range N/A - N/A
Shares Out 723,000.00
Stochastic %K 60%
Beta 1.03
Analysts Strong Buy
Price Target N/A

Latest News on SXTC

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

Mar 17, 2025, 8:30 AM EDT - 4 weeks ago

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

Feb 21, 2025, 12:35 PM EST - 2 months ago

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Oct 7, 2024, 4:15 PM EDT - 6 months ago

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule

Oct 26, 2023, 4:05 PM EDT - 1 year ago

China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule

China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split

Oct 4, 2023, 8:30 AM EDT - 1 year ago

China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split

China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

May 18, 2022, 12:30 PM EDT - 3 years ago

China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million

Mar 14, 2022, 10:33 PM EDT - 3 years ago

China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC).

Jan 20, 2022, 12:30 PM EST - 3 years ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC).

China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment

Jan 20, 2022, 10:45 AM EST - 3 years ago

China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment

China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares

Jan 18, 2022, 6:47 AM EST - 3 years ago

China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares

China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares

Jan 14, 2022, 5:43 PM EST - 3 years ago

China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares

China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin

Jan 14, 2022, 2:30 PM EST - 3 years ago

China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin

China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection

Oct 18, 2021, 8:00 AM EDT - 3 years ago

China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection

China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split

Feb 19, 2021, 8:00 AM EST - 4 years ago

China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split